Indication
Unresectable Melanoma
1 clinical trial
3 products
Clinical trial
An Open-label, Multicenter, Dose-escalation, Phase 1b/2 Study of the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of RTA 408 in Combination With Ipilimumab or Nivolumab in the Treatment of Patients With Unresectable or Metastatic MelanomaStatus: Completed, Estimated PCD: 2018-05-09
Product
OmaveloxoloneProduct
IpilimumabProduct
Nivolumab